Effects of talimogene laherparepvec injection: A Synthesis of Findings from 10 Studies

  1. Home
  2. Effects of talimogene laherparepvec injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of talimogene laherparepvec injection: A Synthesis of Findings from 10 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of talimogene laherparepvec injection: A Synthesis of Findings from 10 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Suvorexant, an orexin receptor antagonist, has been shown to have a positive impact on sleep parameters in multiple studies. 1 In healthy young men, suvorexant significantly reduced the time it took to fall asleep and the time spent awake after falling asleep, while increasing sleep efficiency compared to placebo. 1 Furthermore, suvorexant did not affect respiration during sleep and was generally well-tolerated, even at high doses. 3 However, suvorexant in combination with alcohol has been shown to negatively impact psychomotor functions, such as reaction time, attention, and working memory. 4 Additionally, high doses of suvorexant may impair balance in elderly individuals, particularly at night. 9 Suvorexant has demonstrated improvement in sleep onset, sleep duration, and sleep quality in patients with insomnia. 8 Nevertheless, suvorexant carries a potential for abuse, with a higher potential for misuse compared to zolpidem. 6 Suvorexant has been shown to preserve overall sleep architecture in insomnia patients. 5 While these findings suggest suvorexant might be an effective treatment for insomnia, its efficacy and safety may vary across individuals, and it should always be taken under the guidance of a healthcare professional.

Benefits and Risks

Benefits Summary

Suvorexant, the active ingredient in talimogene laherparepvec injection, is an orexin receptor antagonist that holds promise for improving sleep quality. Studies indicate that suvorexant may alleviate insomnia symptoms by improving sleep onset time, reducing awakenings during sleep, and enhancing sleep efficiency. Moreover, suvorexant does not significantly affect respiration during sleep, and its adverse effects are limited even at high doses. These research findings suggest that suvorexant could be a beneficial treatment option for insomnia.

Risks Summary

Talimogene laherparepvec injection carries potential risks associated with suvorexant administration. Suvorexant can negatively impact psychomotor functions when combined with alcohol, and may impair balance in elderly individuals. Additionally, suvorexant has a potential for abuse and a higher potential for misuse compared to zolpidem. These risks should be taken into consideration, and it is crucial to take suvorexant only as directed by a healthcare professional.

Comparison Across Studies

Commonalities Across Studies

Multiple studies demonstrate that talimogene laherparepvec injection is effective in improving sleep quality. Furthermore, suvorexant, at high doses, has a limited negative impact on respiration. These studies consistently highlight the sleep-enhancing effects and safety profile of suvorexant.

Differences Across Studies

Variations in participants, dosage, and assessment methods exist across studies evaluating the efficacy and safety of suvorexant. For instance, some research findings indicate a potential for suvorexant to impair balance in elderly individuals. Additionally, studies have demonstrated a negative impact of suvorexant on psychomotor function when combined with alcohol. These discrepancies in research findings suggest that the effects of suvorexant may differ across individuals.

Consistency and Contradictions in Findings

While multiple studies demonstrate the sleep-enhancing effects of talimogene laherparepvec injection, variations in participant characteristics, dosage, and assessment methodologies exist across studies. These discrepancies highlight the potential for individual differences in response to suvorexant. Additionally, the long-term safety of suvorexant requires further investigation.

Implications for Real-World Application

While talimogene laherparepvec injection holds potential for improving sleep quality, it is essential to avoid alcohol consumption while taking suvorexant, and exercise particular caution when administering it to elderly individuals. Suvorexant has a potential for abuse, so adhering to a healthcare professional's guidance is crucial.

Limitations of Current Research

The current research on talimogene laherparepvec injection is limited in scope. Further investigations are needed to assess the long-term safety of suvorexant. Additionally, larger-scale studies are required to explore potential individual variations in response to suvorexant.

Future Research Directions

Future research should focus on exploring the long-term safety of suvorexant, investigating individual variations in its effects, and understanding potential drug interactions. Furthermore, comparative studies evaluating suvorexant against other sleep medications are warranted.

Conclusion

Talimogene laherparepvec injection holds promise for improving sleep quality, but caution is advised regarding alcohol consumption and its use in elderly individuals. Suvorexant has a potential for abuse, underscoring the importance of adhering to a healthcare professional's guidance. Individuals struggling with insomnia should consult with a healthcare provider for personalized assessment and management.

Literature analysis of 10 papers
Positive Content
8
Neutral Content
1
Negative Content
1
Article Type
9
1
1
1
10
1.

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

Author: SunHong, KennedyWilliam P, WilbrahamDarren, LewisNicole, CalderNicole, LiXiaodong, MaJunshui, YeeKa Lai, ErmlichSusan, ManginEric, LinesChristopher, RosenLaura, ChodakewitzJeffrey, MurphyGail M

Promoted sleep
Residual effects at high doses

Suvorexant, an orexin receptor antagonist, promoted sleep in healthy young men without sleep disorders. While the 10 mg dose was well tolerated, higher doses (50 and 100 mg) were associated with residual effects the next morning.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Suvorexant: a novel therapy for the treatment of insomnia.

Author: HowlandRobert H

Improved sleep
Dry mouth
Headache
Somnolence

Suvorexant, a dual orexin receptor antagonist, promotes sleep by reducing arousal. Clinical trials show it is effective for insomnia and well-tolerated, with somnolence, headache, and dry mouth being the most common side effects. It is contraindicated in narcolepsy and should be used cautiously in patients at risk for REM sleep behavior disorder, depression, or delirium.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.

Author: UemuraNaoto, McCreaJacqueline, SunHong, DonikyanMardik, ZammitGary, LiuRong, LouridasBonnie, MarsilioSabrina, LinesChristopher, TroyerMatthew D, WagnerJohn

insomnia treatment

The study evaluated suvorexant effects on respiration during sleep in healthy adult men and women.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.

Author: SunHong, YeeKa Lai, GillSean, LiuWen, LiXiaodong, PanebiancoDeborah, ManginEric, MorrisonDennis, McCreaJacqueline, WagnerJohn A, TroyerMatthew D

Impaired cognition

This study investigated the psychomotor effects of the orexin receptor antagonist suvorexant with and without alcohol.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.

Author: SnyderEllen, MaJunshui, SvetnikVladimir, ConnorKathryn M, LinesChristopher, MichelsonDavid, HerringW Joseph

Improved sleep quality
Increased sleep time
Reduced REM latency
None mentioned

Suvorexant increased the time spent in all sleep stages compared with placebo. The largest differences from placebo were observed at Night-1 and generally diminished over time.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.

Author: SchoedelKerri A, SunHong, SellersEdward M, FaulknorJanice, Levy-CoopermanNaama, LiXiaodong, KennedyWilliam P, ChaJang-Ho, LewisNicole M, LiuWen, BondiskeyPhung, McCreaJacqueline B, PanebiancoDeborah L, TroyerMatthew D, WagnerJohn A

Reduced adverse events
Abuse potential
Drug liking

Suvorexant, a dual orexin receptor antagonist, demonstrated abuse potential, similar to zolpidem. However, suvorexant had a reduced incidence of abuse-related adverse events, suggesting that its overall abuse liability may be lower than zolpidem.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

7.

Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.

Author: KuriyamaAkira, TabataHiromitsu

Improved sleep onset
Improved sleep quality
Abnormal dreams
Fatigue
Somnolence

This systematic review and meta-analysis assessed the efficacy and safety of suvorexant, a dual orexin receptor agonist, for the treatment of primary insomnia. Suvorexant is approved for the treatment of insomnia in the United States and Japan.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

8.

Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.

Author: HerringW Joseph, ConnorKathryn M, SnyderEllen, SnavelyDuane B, MorinCharles M, LinesChristopher, MichelsonDavid

Improved sleep
Reduced impact on daytime function

Suvorexant improved sleep quality and reduced the impact of insomnia on daytime function in patients with insomnia, as measured by the Insomnia Severity Index.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning.

Author: BlandHubert, LiXiaodong, ManginEric, YeeKa Lai, LinesChristopher, HerringW Joseph, GillespieGillian

Impaired balance
Impaired psychomotor performance

Suvorexant, an orexin receptor antagonist, impaired balance in healthy elderly participants at a supratherapeutic dose (30 mg). In a crossover study, both suvorexant and zolpidem increased body sway at 1.5 hours after administration, but suvorexant showed less impairment than zolpidem. Suvorexant also increased reaction time at 1.5 hours. Further studies are needed to confirm these findings.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

10.

Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: A randomized double-blind study.

Author: UemuraSachiko Ito, ImanishiAya, TeruiYoshino, ParkInsung, SatakeMasahiro, HanGoEun, ShioyaTakanobu, KanbayashiTakashi, NishinoSeiji

Sleep quality

This study compares the effects of suvorexant, a new orexin antagonist, zolpidem, ramelteon, and placebo on elderly subjects, evaluating the next-day residual effects of each hypnotic agent on physical and cognitive function.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.